Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting
December 09, 2019 10:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 12, 2019 08:00 ET
|
SpringWorks Therapeutics, Inc.
– Commenced Phase 2b ReNeu Clinical Trial for Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) – – Received Important Regulatory Designations for Nirogacestat...
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)
October 24, 2019 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma
September 24, 2019 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Sept. 24, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares
September 17, 2019 16:05 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Sept. 17, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
SpringWorks Therapeutics Announces Pricing Of Initial Public Offering
September 12, 2019 18:15 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Sept. 12, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe...